ABSTRACT
0.05).The main side effects were myelosuppresion,gastrointestinal reation and peripheral nerve toxicity and phlebitis.Conclusion The therapeutic effectiveness of NP regimen was better than MVP regimen.There were no significant difference between the two regimens.They can be used as first line chemotheapy for NSCLC.
ABSTRACT
0.05). No significant differences were detected in the median time of remission, median survival time and 1-, 2-year survival rates between the groups. Moreover, no significant differences were detected in the grade Ⅲ～Ⅳ leukopenia, grade Ⅲ～Ⅳ thrombocytopenia, grade Ⅲ～Ⅳ nausea and vomiting and grade Ⅲ～Ⅳ constipation between the groups. Conclusions:The response rate of the MVP regimen is slightly lower than the HMVP regimen, but the HMVP regimen is not noticeably superior. It may increase the toxicity such as leukopenia, nausea/vomiting and constipation, as wellas being more expensive. In short, MVP regimen should be selected between the regimens in the chemotherapy of advanced NSCLC.
ABSTRACT
Purpose:To compare taxol,cisplatin(TP) and mitomycin, vinorelbine and cisplatin (MNP) with mitomycin,vindesine and cisplatin (MVP) and to evaluate the efficacy of the three regimens in patients with advanced non small cell lung cancer (NSCLC).Methods: One hundred and ten patients were enrolled in this study, 27 on TP, 40 on MNP and 43 on MVP. The characteristics of patients were comparable.Results:An objective response rate was observed in 51.9% of patients in the TP arm, 45.0% of patients in the MNP arm versus 32.6% in the MVP arm. The median duration of survival was 11.2 months in the TP arm, compared with 10.5 months in the MNP arm and 8.1 months in the MVP arm. The progression free survival was 9.0 months、8.0 months and 6.8 months in the TP、MNP and MVP arms, respectively. The major toxicities were bone marrow suppression、nausea、vomiting and alopecia.Conclusions:TP had a higher response rate than MNP and MVP, with acceptable toxicity. Its efficacy should be confirmed through a randomized study.
ABSTRACT
Purpose:To study the effect of amifostine on ef ficacy in patients with advanced non-small-cell lung cancer(NSCLC) treated w ith chemotherapy and the protection of amifostine on myelosuppression induced by chemotherapy and to investigate major adverse reaction induced by amfostine. Methods:33 patients with advanced NSCLC were randomly divided i nto protection group (amosfostine + MMC +VDS + DDP) and control group (MMC + VDS + DDP), The regimen was given every 4 weeks , All enrolled patients were evalua ted for efficacy and hematologic toxicity after 3 cycles of treatment , Patients in both groups were well-matched for baseline disease characteristics. Results:In protection group (PG) , the response rate was 40% (1 CR , 5 PR , 6 NC , 3 PD), whereas in control group (CG) , the response rate was 33.3% (0 CR , 5 CR , 8 NC , 2 PD), the differentce of response rates betwee n two the groups was not statistically significant (P=0.705). The minimum wh ite blood cell (WBC) counts after chemotherapy in treatment group and in control group were (3.387?1.169)?109/L and (2.46?0.98)?109/L respectively (P =0.026). The minimum blood platelet cell (BPC) counts in PG and in CG were (11 4.53?48.24)?109 /L and (88.2?32.83)?109 /L respectively (P=0.091) . The minimum hemoglobin (HB) counts in CG and in CG were (94.4?14.69)g/L and (89 .33?13.98)g/L respectively (P=0.341). Grade (Ⅱ-Ⅳ) leukopenia rate in PG and in CG were 66.7% (10/15) and 33.3% (5/15) respectively (P= 0.068), Gr ade (Ⅱ-Ⅳ) thrombocytopenia rate in PG and in CG were 33.3% (5/15) and 20% (3/ 15) respectively (P= 0.409), Grade (Ⅱ-Ⅳ) hypochromia rate in PG and in CG were 53.3% (8/15) and 46.7% (7/15) respectively (P= 0.715). Major ad verse effects of amifostine were mild hypotension , nausea and vomiting , dizzin ess , malaise etc. Conclusions:Amifostine does not reduce the efficacy of chemothe rapy in patients with advanced NSCLC , it can reduce the hematologic toxicity as sociated with chemotherapy of MVP regimen , the adverse effects of amifostine ar e mild.